no code implementations • 5 Feb 2024 • Annie Liang, Thomas Jemielita, Andy Liaw, Vladimir Svetnik, Lingkang Huang, Richard Baumgartner, Jason M. Klusowski
Recently, several adjustments to marginal permutation utilizing feature knockoffs were proposed to address this issue, such as the variable importance measure known as conditional predictive impact (CPI).
no code implementations • 4 Sep 2023 • Shaoyan Pan, Yiqiao Liu, Sarah Halek, Michal Tomaszewski, Shubing Wang, Richard Baumgartner, Jianda Yuan, Gregory Goldmacher, Antong Chen
In oncology research, accurate 3D segmentation of lesions from CT scans is essential for the modeling of lesion growth kinetics.
no code implementations • 28 Jun 2022 • Arash A. Amini, Richard Baumgartner, Dai Feng
We show that for polynomial alignment, there is an \emph{over-aligned} regime, in which TKRR can achieve a faster rate than what is achievable by full KRR.
no code implementations • 19 Aug 2021 • Dai Feng, Richard Baumgartner
Kernels ensuing from tree ensembles such as random forest (RF) or gradient boosted trees (GBT), when used for kernel learning, have been shown to be competitive to their respective tree ensembles (particularly in higher dimensional scenarios).
no code implementations • 19 Dec 2020 • Dai Feng, Richard Baumgartner
We elucidate the performance and properties of the RF and GBT based kernels in a comprehensive simulation study comprising of continuous and binary targets.
no code implementations • 31 Aug 2020 • Dai Feng, Richard Baumgartner
We elucidate the performance and properties of the data driven RF kernels used by regularized linear models in a comprehensive simulation study comprising of continuous, binary and survival targets.
no code implementations • 5 Mar 2020 • Antong Chen, Jennifer Saouaf, Bo Zhou, Randolph Crawford, Jianda Yuan, Junshui Ma, Richard Baumgartner, Shubing Wang, Gregory Goldmacher
Herein we propose a deep learning-based approach for the prediction of lung lesion response based on radiomic features extracted from clinical CT scans of patients in non-small cell lung cancer trials.